Company Profile

LYSOGENE is a biotechnology company specializing in the research and development of gene therapies for the treatment of rare neurodegenerative diseases. The company now has 2 drug candidates in clinical development of which 1 in phase 2/3 (LYS-SAF302 for the treatment of Sanfilippo syndrome type A) and 1 in phase 1/2 (LYS-GM101 for the treatment of GM1 gangliosidosis).

Employees

Sector

Biotechnology & Medical Research

More about the company

06/23/06	Lysogene S.A.(ENXTPA:LYS) dropped from CAC AllShares Index	CI
06/23/06	Lysogene S.A.(ENXTPA:LYS) dropped from Next Biotech Index	CI
14/23/14	Lysogene CFO Assumes Same Role at Mauna Kea Technologies	MT
29/23/29	Lysogene: placed in liquidation and delisted
29/23/29	Lysogene to Delist from Euronext amid Judicial Liquidation	MT
29/23/29	Lysogene S.A. Announces Postponement of 2022 Financial Results Release	CI
17/23/17	Lysogene: no takeover bid received for biotech company
17/23/17	Lysogene Fails to Secure Takeover Bid Amid Reorganization	MT
27/23/27	Lysogene: deadline for takeover bids extended
06/23/06	Lysogene: interim CFO confirmed
06/23/06	French Gene Therapy Group Lysogene Makes Ad Interim CFO Permanent	MT
03/23/03	Lysogene Appoints Côme de La Tour du Pin as Chief Financial Officer	CI
25/23/25	Lysogene: company placed in receivership

10/23/10	Fragile X Syndrome Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	AQ
18/23/18	Fragile X Syndrome Pipeline, Clinical Trials and NDA Approvals 2023 (Updated)	AQ
29/23/29	LYSOGENE : Inside Information / News release on accounts, results	PU
07/22/07	LYSOGENE : Inside Information / Operations of the issuer (acquisitions, sales...)	PU
30/22/30	Lysogene : Announces Favorable DSMB Review Recommending Study Continuation and Positive Biomarker Data in Stage 1 of Adaptative Clinical Trial with LYS-GM101 Gene Therapy in GM1 Gangliosidosis	PU

14/23/14	Mauna Kea Technologies : A suivre aujourd'hui
13/23/13	Mauna Kea Technologies : Côme de La Tour du Pin (ex-Lysogene) nommé Directeur financier
29/23/29	Lysogene : placé en liquidation et retiré de la cote
16/23/16	Lysogène: audience le 23 mai sur une possible liquidation judiciaire
02/23/02	Lysogene : reporte la publication de ses résultats et envisage une liquidation judiciaire

Manager	Title	Age	Since
Karen Pignet-Aiach CEO	Chief Executive Officer	54	09/05/2014
Côme de La Tour du Pin DFI	Director of Finance/CFO	-	01/11/2022
Marie Trad CTO	Chief Tech/Sci/R&D Officer	-	01/02/2022

Director	Title	Age	Since
Karen Pignet-Aiach CHM	Chairman	54	22/05/2019
Peter Lichtlen BRD	Director/Board Member	58	01/04/2018
Carole Deffez BRD	Director/Board Member	-	26/09/2019

LYSOGENE Share Price

Stocks

LYS

FR0013233475

Biotechnology & Medical Research

Latest news : LYSOGENE

Press Releases: LYSOGENE

News in other languages: LYSOGENE

Managers and Directors: LYSOGENE

Bio Diagnostics & Testing

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LYSOGENE	-.--%	-.--%	-	-	55.26L
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-3.13%	-0.57%	+93.21%	+288.25%	402.98Cr
VERACYTE, INC.	-4.66%	-7.69%	+48.07%	+69.38%	359.19Cr
IOVANCE BIOTHERAPEUTICS, INC.	-3.26%	+50.23%	+192.38%	-7.65%	305.3Cr
CAREDX, INC.	+0.15%	+4.13%	+280.26%	+432.36%	244.75Cr
BGI GENOMICS CO., LTD.	+3.97%	+6.34%	-19.72%	-28.79%	229.61Cr
FREENOME, INC.	-3.75%	+5.87%	+9.27%	-	130.35Cr
SEEGENE, INC.	-0.16%	+13.73%	+17.28%	+44.02%	102.73Cr
MARAVAI LIFESCIENCES HOLDINGS, INC.	0.00%	-9.83%	+114.87%	-44.10%	86Cr
HANGZHOU ALLTEST BIOTECH CO., LTD.	+0.75%	+10.50%	-36.33%	-0.10%	56Cr
Average	-1.01%	+8.52%	+77.70%	+94.17%	213.04Cr
Weighted average by Cap.	-1.80%	+10.57%	+98.29%	+133.56%